The mm Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the mm Hub cannot guarantee the accuracy of translated content. The mm and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Multiple Myeloma Hub is an independent medical education platform, sponsored by Bristol Myers Squibb, GSK, Johnson & Johnson, Pfizer, Roche and Sanofi. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View mm content recommended for you
Jesús San MiguelVideo series
During the 25th Congress of the European Hematology Association (EHA), the Multiple Myeloma (MM) Hub spoke to Jesús San Miguel, University of Navarra, Pamplona, ES about the management of patients with high-risk MM.
Despite emerging treatments for patients with MM, the prognosis of patients with high-risk cytogenetics remains inferior to those with standard-risk disease. Could early intervention with novel therapies, such as CAR T-cell therapy and bispecific antibodies, improve the outcomes of patients with high-risk MM?
In this interview, Jesús San Miguel discusses the safety and efficacy of the B-cell maturation antigen-targeted CAR T-cell therapy, idecabtagene vicleucel (ide-cel; bb2121), in patients with relapsed/refractory MM.
More from this series:
